Core Viewpoint - The announcement details the planned share reduction by the controlling shareholder and actual controller of Yirui Biological, which is not expected to significantly impact the company's governance structure or control [1][2]. Group 1: Share Reduction Plan - Yirui (Hainan) Venture Capital Co., Ltd., the controlling shareholder, plans to reduce its holdings by up to 3,531,208 shares, representing 0.88% of the total share capital [1]. - The actual controller, Zhu Hai, intends to reduce his holdings by up to 7,521,390 shares, accounting for 1.87% of the total share capital [1]. - The total planned reduction by both parties does not exceed 3% of the company's total share capital, with specific limits on the number of shares that can be sold within a 90-day period [1]. Group 2: Company Background and Financials - Yirui Biological was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on February 9, 2021, with an initial issuance of 40.86 million shares at a price of 5.31 yuan per share, raising a total of 217 million yuan [2]. - The company has raised a total of 545 million yuan from two fundraising events, with the first round netting 175 million yuan after expenses [3][4]. - The net profit attributable to shareholders for the years 2021, 2022, 2023, and 2024 were 236.51 million yuan, 82.97 million yuan, -184.91 million yuan, and 17.12 million yuan, respectively [4][5]. Group 3: Financial Performance - In 2024, the company's operating revenue is projected to be 224.25 million yuan, a decrease of 11.75% from 2023 [5]. - The net profit attributable to shareholders is expected to increase by 109.26% in 2024, reaching 17.12 million yuan, compared to a loss of 184.91 million yuan in 2023 [5]. - The cash flow from operating activities showed a significant improvement, with a net cash flow of 34.26 million yuan in 2024, compared to a negative cash flow of -37.25 million yuan in 2023, marking a 191.97% increase [5].

Core Viewpoint - The share reduction plan by major shareholders of Yirui Biological has been completed, resulting in a total cash-out of approximately 8.83 million yuan from the sales of shares [1][2]. Shareholder Reduction Summary - Yirui Biological's major shareholders, Yidari and Yikairei, executed their share reduction plans, with Yidari reducing 411,200 shares (0.1025% of total shares) and Yikairei reducing 575,700 shares (0.1435% of total shares) [1][3]. - Yidari's share reduction occurred through concentrated bidding and block trading, with an average price of 9.33 yuan per share for 116,200 shares and 8.76 yuan per share for 295,000 shares [3]. - Yikairei's share reduction also involved concentrated bidding and block trading, with an average price of 9.30 yuan per share for 275,700 shares and 8.66 yuan per share for 300,000 shares [3]. Shareholder Equity Changes - Shareholder Wang Tianyi reduced his holdings by 6,337,700 shares (1.5792% of total shares) from April 25 to June 6, 2025, bringing his total holdings down to 20,065,821 shares (4.999984% of total shares) [2][4]. - Wang Tianyi's reduction means he is no longer a major shareholder with over 5% ownership [2][4]. Company Financial Activities - Yirui Biological raised a total of 217 million yuan during its IPO, with a net amount of 175 million yuan after deducting issuance costs [6]. - The company issued convertible bonds worth 328.2 million yuan in August 2023, which began trading on September 6, 2023 [7].